Bristol-Myers Squibb Company (BMY) Position Lowered by Thompson Siegel & Walmsley LLC
Thompson Siegel & Walmsley LLC lessened its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 3.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,223 shares of the biopharmaceutical company’s stock after selling 531 shares during the quarter. Thompson Siegel & Walmsley LLC’s holdings in Bristol-Myers Squibb were worth $848,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. State Street Corp raised its stake in shares of Bristol-Myers Squibb by 1.8% during the 1st quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after acquiring an additional 1,223,457 shares in the last quarter. Jennison Associates LLC raised its stake in shares of Bristol-Myers Squibb by 5.4% during the 2nd quarter. Jennison Associates LLC now owns 23,118,789 shares of the biopharmaceutical company’s stock worth $1,288,179,000 after acquiring an additional 1,184,652 shares in the last quarter. Ameriprise Financial Inc. raised its stake in shares of Bristol-Myers Squibb by 18.7% during the 1st quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after acquiring an additional 2,451,390 shares in the last quarter. Legal & General Group Plc raised its stake in shares of Bristol-Myers Squibb by 2.7% during the 2nd quarter. Legal & General Group Plc now owns 8,431,348 shares of the biopharmaceutical company’s stock worth $469,802,000 after acquiring an additional 217,920 shares in the last quarter. Finally, Swiss National Bank raised its stake in shares of Bristol-Myers Squibb by 3.2% during the 2nd quarter. Swiss National Bank now owns 6,111,570 shares of the biopharmaceutical company’s stock worth $340,537,000 after acquiring an additional 189,900 shares in the last quarter. Hedge funds and other institutional investors own 68.97% of the company’s stock.
Bristol-Myers Squibb Company (BMY) opened at $60.80 on Tuesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. The firm has a market cap of $99,510.00, a PE ratio of 20.72, a price-to-earnings-growth ratio of 2.42 and a beta of 1.18. Bristol-Myers Squibb Company has a 12 month low of $46.01 and a 12 month high of $66.10.
Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). The company had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.20 billion. Bristol-Myers Squibb had a return on equity of 22.99% and a net margin of 16.29%. The company’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period last year, the business earned $0.77 EPS. equities analysts forecast that Bristol-Myers Squibb Company will post 2.99 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th were paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 2.57%. The ex-dividend date was Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 61.42%.
TRADEMARK VIOLATION NOTICE: This article was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.thecerbatgem.com/2017/11/21/bristol-myers-squibb-company-bmy-position-lowered-by-thompson-siegel-walmsley-llc.html.
Several analysts have weighed in on BMY shares. Hilliard Lyons downgraded shares of Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 target price on the stock. in a research report on Tuesday, September 12th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and set a $65.00 target price (up previously from $62.00) on shares of Bristol-Myers Squibb in a research report on Thursday, September 7th. SunTrust Banks, Inc. raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Monday, October 30th. Zacks Investment Research raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $68.00 price objective on the stock in a report on Wednesday, November 1st. Finally, Barclays PLC upped their price objective on shares of Bristol-Myers Squibb from $58.00 to $65.00 and gave the company an “equal weight” rating in a report on Friday, October 13th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $64.93.
In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the transaction, the senior vice president now owns 46,297 shares of the company’s stock, valued at $2,777,820. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.